BioCentury | Apr 10, 2019
Distillery Therapeutics

Imidazopyrimidine-based inhibitor of Leishmania proteasome identified to treat visceral leishmaniasis

...respectively. Ongoing work by GlaxoSmithKline plc includes testing GSK3494245 in preclinical models of visceral leishmaniasis. Knight Therapeutics Inc....
BioCentury | Oct 11, 2017
Company News

Management tracks: Aerpio, Scancell, TCR2

...business unit at the Fresenius Kabi subsidiary of Fresenius SE & Co. KGaA (Xetra:FRE; OTCQX:FSNUY). Knight Therapeutics Inc....
BioCentury | Aug 24, 2017
Translation in Brief

The skinny on leishmaniasis

...and Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506); and Impavido miltefosine, a cholinephosphate cytidyltransferase inhibitor, from Knight Therapeutics Inc....
BioCentury | Aug 11, 2017
Company News

FDA reviewing Gilead's NDA for HIV triple therapy

...a Priority Review voucher to speed approval of HIV drug Odefsey rilpivirine/emtricitabine/tenofovir alafenamide. It paid Knight Therapeutics Inc....
BioCentury | Jul 18, 2017
Distillery Therapeutics

Infectious disease

...Next steps could including testing the flotillin inhibitors in additional models of S. aureus infections. Knight Therapeutics Inc....
...Profounda Inc. , Roche , and Zydus Cadila Group market Impavido to treat leishmaniasis. Knight Therapeutics...
BioCentury | Jul 3, 2017
Preclinical News

Paper names scaffold protein as target for infection

...evaluated flotillin small molecule inhibitors including Impavido miltefosine , zaragozic acid and 5-doxyl-stearic acid (5-DSA). Knight Therapeutics Inc....
...Impavido to treat leishmaniasis. The drug is an alkylphosphocholine analog that inhibits cholinephosphate cytidyltransferase . Chris Lieu Impavido Miltefosine Knight Therapeutics Inc. Profounda...
BioCentury | Feb 22, 2017
Company News

Gilead buys Sarepta PRV, mum on plans

...Gilead used a voucher to speed approval of HIV drug Odefsey rilpivirine/emtricitabine/tenofovir alafenamide. It paid Knight Therapeutics Inc....
BioCentury | Feb 22, 2017
Distillery Therapeutics

Infectious disease

...hours. Next steps could include optimizing and testing the compound in additional models of leishmaniasis. Knight Therapeutics Inc....
...Profunda Inc. , Roche , and Zydus Cadila Group market Impavido miltefosine to treat leishmaniasis. Knight Therapeutics...
BioCentury | Jan 6, 2017
Finance

Good riddance

...12/30 Mcap % chg Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) (A) 12/28/16 $28.7 NA $108.3 NA Knight Therapeutics Inc....
BioCentury | Dec 30, 2016
Financial News

Knight Therapeutics completes follow-on

...and TD Securities. The figures include a 1.3 million share overallotment. Knight Therapeutics Inc. (TSX:GUD), Westmount, Quebec Alex Himes Knight Therapeutics Inc....
Items per page:
1 - 10 of 53
BioCentury | Apr 10, 2019
Distillery Therapeutics

Imidazopyrimidine-based inhibitor of Leishmania proteasome identified to treat visceral leishmaniasis

...respectively. Ongoing work by GlaxoSmithKline plc includes testing GSK3494245 in preclinical models of visceral leishmaniasis. Knight Therapeutics Inc....
BioCentury | Oct 11, 2017
Company News

Management tracks: Aerpio, Scancell, TCR2

...business unit at the Fresenius Kabi subsidiary of Fresenius SE & Co. KGaA (Xetra:FRE; OTCQX:FSNUY). Knight Therapeutics Inc....
BioCentury | Aug 24, 2017
Translation in Brief

The skinny on leishmaniasis

...and Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506); and Impavido miltefosine, a cholinephosphate cytidyltransferase inhibitor, from Knight Therapeutics Inc....
BioCentury | Aug 11, 2017
Company News

FDA reviewing Gilead's NDA for HIV triple therapy

...a Priority Review voucher to speed approval of HIV drug Odefsey rilpivirine/emtricitabine/tenofovir alafenamide. It paid Knight Therapeutics Inc....
BioCentury | Jul 18, 2017
Distillery Therapeutics

Infectious disease

...Next steps could including testing the flotillin inhibitors in additional models of S. aureus infections. Knight Therapeutics Inc....
...Profounda Inc. , Roche , and Zydus Cadila Group market Impavido to treat leishmaniasis. Knight Therapeutics...
BioCentury | Jul 3, 2017
Preclinical News

Paper names scaffold protein as target for infection

...evaluated flotillin small molecule inhibitors including Impavido miltefosine , zaragozic acid and 5-doxyl-stearic acid (5-DSA). Knight Therapeutics Inc....
...Impavido to treat leishmaniasis. The drug is an alkylphosphocholine analog that inhibits cholinephosphate cytidyltransferase . Chris Lieu Impavido Miltefosine Knight Therapeutics Inc. Profounda...
BioCentury | Feb 22, 2017
Company News

Gilead buys Sarepta PRV, mum on plans

...Gilead used a voucher to speed approval of HIV drug Odefsey rilpivirine/emtricitabine/tenofovir alafenamide. It paid Knight Therapeutics Inc....
BioCentury | Feb 22, 2017
Distillery Therapeutics

Infectious disease

...hours. Next steps could include optimizing and testing the compound in additional models of leishmaniasis. Knight Therapeutics Inc....
...Profunda Inc. , Roche , and Zydus Cadila Group market Impavido miltefosine to treat leishmaniasis. Knight Therapeutics...
BioCentury | Jan 6, 2017
Finance

Good riddance

...12/30 Mcap % chg Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) (A) 12/28/16 $28.7 NA $108.3 NA Knight Therapeutics Inc....
BioCentury | Dec 30, 2016
Financial News

Knight Therapeutics completes follow-on

...and TD Securities. The figures include a 1.3 million share overallotment. Knight Therapeutics Inc. (TSX:GUD), Westmount, Quebec Alex Himes Knight Therapeutics Inc....
Items per page:
1 - 10 of 53